Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
10
×
boston top stories
life sciences
national blog main
national top stories
biotech
clinical trials
boston
san francisco blog main
new york blog main
san diego blog main
new york top stories
san diego top stories
san francisco top stories
cancer
indiana blog main
indiana top stories
national
blueprint medicines
boulder/denver blog main
boulder/denver top stories
crispr
depression
detroit blog main
detroit top stories
drugs
dyne therapeutics
editas medicine
fda
myotonic dystrophy type 1
raleigh-durham blog main
raleigh-durham top stories
rare disease drugs
rare diseases
roche
seattle blog main
seattle top stories
texas blog main
texas top stories
third rock ventures
What
genetic
10
×
medicines
drug
new
cancer
fda
ipo
medicine
rare
ago
approved
biotech
company
diseases
dyne
editing
experimental
gene
million
muscle
oks
raised
research
therapeutics
treatment
abbvie
address
aims
akcea
alliance
alnylam
amyloidosis
analysis
approval
approves
attr
available
backed
battle
bio
Language
unset
Current search:
genetic
×
" boston blog main "
×
@xconomy.com
4 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Will New Study Cut Guesswork for Depression Medicine Prescriptions?